Ignite Creation Date:
2024-05-05 @ 9:53 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001173
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization
Status:
COMPLETED
Status Verified Date:
1999-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
One of the major interests of this laboratory is the characterization of the cellular subpopulations involved in the triggering and immunoregulation of B lymphocytes to produce antibodies We are assessing the responses of individuals to produce antibodies against newly encountered antigens such as keyhole limpet hemocyanin KLH approved project number 77-I-0130 and propose to assess the amnestic responses to the previously encountered antigen tetanus toxoid The purpose of this protocol is to add this recall antigen to our repertoire of antigens used to evaluate the immune response in man
Booster immunization with tetanusdiphtheria toxoid has now been used for several years by a number of clinical immunology laboratories throughout the country to assess B cell related immunologic profiles in patients and control normal subjects We have recently developed a sensitive ELISA assay for IgM and IgG in vitro specific antibody responses against tetanus toxoid This will allow us to carefully and precisely monitor the evolution and immunoregulation of the human B cell responses to this recall antigen This is of particular importance and relevance to us in our ongoing studies of a number of diseases characterized by abnormalities of immunologic reactivity including those treated with various regimens of immunosuppressive agents
Booster immunization with tetanusdiphtheria toxoid has now been used for several years by a number of clinical immunology laboratories throughout the country to assess B cell related immunologic profiles in patients and control normal subjects We have recently developed a sensitive ELISA assay for IgM and IgG in vitro specific antibody responses against tetanus toxoid This will allow us to carefully and precisely monitor the evolution and immunoregulation of the human B cell responses to this recall antigen This is of particular importance and relevance to us in our ongoing studies of a number of diseases characterized by abnormalities of immunologic reactivity including those treated with various regimens of immunosuppressive agents
Detailed Description:
One of the major interests of this laboratory is the characterization of the cellular subpopulations involved in the triggering and immunoregulation of B lymphocytes to produce antibodies We are assessing the responses of individuals to produce antibodies against newly encountered antigens such as keyhole limpet hemocyanin KLH approved project number 77-I-0130 and propose to assess the amnestic responses to the previously encountered antigen tetanus toxoid The purpose of this protocol is to add this recall antigen to our repertoire of antigens used to evaluate the immune response in man
Booster immunization with tetanusdiphtheria toxoid has now been used for several years by a number of clinical immunology laboratories throughout the country to assess B cell related immunologic profiles in patients and control normal subjects We have recently developed a sensitive ELISA assay for IgM and IgG in vitro specific antibody responses against tetanus toxoid This will allow us to carefully and precisely monitor the evolution and immunoregulation of the human B cell responses to this recall antigen This is of particular importance and relevance to us in our ongoing studies of a number of diseases characterized by abnormalities of immunologic reactivity including those treated with various regimens of immunosuppressive agents
Booster immunization with tetanusdiphtheria toxoid has now been used for several years by a number of clinical immunology laboratories throughout the country to assess B cell related immunologic profiles in patients and control normal subjects We have recently developed a sensitive ELISA assay for IgM and IgG in vitro specific antibody responses against tetanus toxoid This will allow us to carefully and precisely monitor the evolution and immunoregulation of the human B cell responses to this recall antigen This is of particular importance and relevance to us in our ongoing studies of a number of diseases characterized by abnormalities of immunologic reactivity including those treated with various regimens of immunosuppressive agents
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 80-I-0070 | None | None | None |